What is MDWD's current stock price?

MDWD (MediWound Ltd.) is currently trading at $16.58 with a market cap of $180.1M.

What sector is MediWound Ltd. in?

MediWound Ltd. (MDWD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MDWD a good stock to buy?

Analysts have a Buy consensus on MDWD with a price target of $32.20. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MDWD MediWound Ltd.

Healthcare

$16.58-1.54%ClosedMarket Cap: $180.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.87

P/S

10.62

EV/EBITDA

-8.57

DCF Value

$-25.51

FCF Yield

-11.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

19.2%

Operating Margin

-149.1%

Net Margin

-140.8%

ROE

-65.8%

ROA

-27.7%

ROIC

-41.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$1.9M	$-7.2M	$—
FY null	$17.0M	$-23.9M	$—
Q3 null	$5.4M	$-2.7M	$—
Q2 null	$5.7M	$-13.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$32.20

Target (Median)

$36.00

Target Range

$25.00 - $39.00

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2025-11-21

Trading Activity

Insider Trades

View All

Driver Vickie Raedirector

SellWed Mar 25

Driver Vickie Raedirector

SellWed Mar 25

Driver Vickie Raedirector

SellWed Mar 25

Driver Vickie Raedirector

SellWed Mar 25

Driver Vickie Raedirector

SellWed Mar 25

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.22

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Peers

IVA

SLS